Pretzel Therapeutics is a Massachusetts-based company (research facilities in Mölndal, Sweden) developing therapies that target cellular energetics to improve survival and quality of life. Its lead program, PX578, recently entered Phase 1 clinical development in the U.S. PX578 aims to restore function to mutant mitochondrial DNA polymerases to repopulate depleted mitochondrial DNA, a strategy targeted at POLG disorders and other mtDNA depletion syndromes. The company positions this approach as having disease‑modifying potential across rare mtDNA depletion syndromes and broader degenerative diseases. There is currently no FDA‑approved therapy for POLG‑related mitochondrial diseases, highlighting a clear unmet need. Pretzel says the new investment from The Mito Fund validates its scientific approach and will support continued development of PX578. Pretzel Therapeutics launched with a $72.5 million Series A to pioneer therapies that modulate mitochondrial biology. Its platform targets mitochondrial function through three primary approaches: genome correction, genome expression modulation, and mitochondrial quality control. The company intends to use the financing to prosecute preclinical development across its pipeline and continue building its team. Pretzel is advancing programs for both rare genetic mitochondrial diseases and more common aging‑related disorders such as Alzheimer’s and Parkinson’s, and sees potential applications in cancer and metabolic diseases. The company was founded by leading academics in mitochondrial biology and is led by experienced drug‑discovery and company‑building executives. Pretzel is headquartered in Waltham, MA, with research facilities in Gothenburg, Sweden.

Total raised

$73M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2022